June 20, 2017 8:06am

 

… Will the upside last?

 

The IBB foretells a positive +0.16% after being up +2.41% while the XBI is also up +0.24%

… The IWM was up +0.74% and is down -0.09%

 

The upside floats like a butterfly but, the downside stings like a bee

 

Pre-open indication:  four (4), 1 BUY and 3 SELLS

 

A critical indication ahead of “our” universe’s open!

 

Are you a subscriber?  If not – you’re missing the realities of “our” universe! 

 

 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

Flat open expected

 

Dow futures are UP +0.01% and NASDAQ futures are UP +0.25%

 

U.S. stock index futures pointed to a flat open on Tuesday, as investors gear up for another batch of remarks from leading Federal Reserve officials.

European markets edged higher during early morning deals, as investors turned their attention to individual stock news and data. Sterling fell to a one-week low of $1.2671 after the Governor of the Bank of England Mark Carney said now is not the time to raise rates.

Asian indexes closed mixed as markets awaited MSCI's decision on the potential inclusion of mainland Chinese stocks, even as the dollar strengthened.

 

Data docket: NONE

 

 

The cell therapy sector closed POSITIVE on Monday, NEGATIVE on Friday, Thursday and Wednesday and POSITIVE last Tuesday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

·         Monday closed POSITIVE with 7 decliners, 35 advancers and 1 flat;

·         Friday closed NEGATIVE with 26 decliners, 14 advancers and 3 flats;

·         Thursday closed NEGATIVE with 31 decliners, 10 advancers and 2 flats;

·         Wednesday closed NEGATIVE with 19 decliners, 18 advancers and 6 flats;

·         Last Tuesday closed POSITIVE with 13 decliners, 25 advancers and 5 flats

 

 

Remembering Monday’s closing bell newsletter, “it was time for the upside to shine. A not unexpected response from a downside trend.”

  • Reiterating, “Upside was motivated by algorithms as news was NOT an upside influence and fundamentals hadn’t changed … at all.”

 

​Where is the attention today, be damned if I know other than who and what ... will stay up ...

​I expect some "wobbly" performance !!

 

 

What did I see on Monday, the DOW closed UP +0.68% (+144.71) as the NASDAQ closed UP +1.42% (+87.25) … with the CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded again near 10.24,  -1.35% following Friday’s trading near 10.4 …

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed up +2.41% on Monday, and indicated a POSITIVE +0.16% in Tuesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Monday up +3.58%, and is indicating a POSITIVE +0.24% In Tuesday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +1.04% Monday, and is NOT indicating in Tuesday’s pre-open;
  • The iShares Russell 2000 (IWM) closed up +0.74% on Monday, and indicating a NEGATIVE -0.09% in Tuesday’s pre-open

 

 

Companies in my headlights:

………. We are back to measuring potential momentum for the sector in this market …….

Juno Therapeutics (JUNO) closed up +$0.91 to $24.20. June started at $24.50; saw a high of $26.21 and a low of $21.68 having seen $24.20 twice in ten sessions.  The aftermarket indication was a positive +$0.49 or +2.02% - BUY;

Kite Pharma (KITE) closed up +$1.44 to $89.29. June started at $74.66; saw a high of $89.71 and a low of $73.61.  The aftermarket indication is a negative -$0.29 or -0.32% - SELL;

Regenxbio (RGNX) closed up +$0.60 to $19.10. June started at $18.00; saw a high of $20.10 and a low of $18.00 having seen $19.10 twice in four sessions – SELL;

Sangamo Therapeutics (SGMO) closed up +$0.50 to $7.95. June started at $7.00; saw a high of $7.95 and a low of $7.00 having seen $7.20 twice in twelve sessions.   I always get “spooked” on some equities as to their direction and SGMO is one of those - SELL

 

 

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.